Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Abstract Background Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are the main incretin hormones, and be responsible for the insulinotropic incretin effect. The addition of a GIP agonist to a GLP-1agonist has been hypothesized to significantly potentiate the weight-losing and glycemia...

Full description

Bibliographic Details
Main Authors: Qian Zhou, Xingxing Lei, Shunlian Fu, Pan Liu, Cong Long, Yanmei Wang, Zinan Li, Qian Xie, Qiu Chen
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Diabetology & Metabolic Syndrome
Subjects:
GLP-1 receptor agonists
Dual GIP/GLP-1 receptor agonist
Tirzepatide
Type 2 diabetes
Meta-analysis
Online Access:https://doi.org/10.1186/s13098-023-01198-4

Internet

https://doi.org/10.1186/s13098-023-01198-4

Similar Items